IL2 and neoplasm: These NK cell-deficient mice were unable to control tumor growth and had a median survival rate of 21.5 days, while mice treated with donor IL-2 NK cells were more resistant to tumor growth and survived longer with half of the mice still alive 70 days after tumor injection (Figure 3B).